Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,HKMPY,1259000000,115386000,37500000,,142000000,13000000,109500000,138500000,318000000,145000000,145000000,-3000000,-8500000,,,,33000000,604500000,459500000,286500000,-3000000,,109000000,109500000,587000000,282000000,1987000000,2135000000,304000000,4135000000,41000000,27000000,1892000000,195000000,289000000,-80000000,235000000,323000000,1028000000,221000000,41000000,-80000000,1068000000,1922000000,34000000,733000000,692000000,757000000,279000000,-1000000,10500000,-91500000,-10500000,-39000000,-12500000,-45000000,-2000000,-500000,86000000,33500000,-29000000,-18000000,-34500000,-50000000,-8500000,27000000,-53000000,894000000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,72.05,1630427382,0.0,72.5,72.05,72.05,360,72.05,0.0,0.0,0,0,finmb_23049465,Other OTC,Hikma Pharmaceuticals PLC,USD,514,300,13.010002,0.22035912,59.04 - 75.81,-3.7599945,-0.049597606,59.04,75.81,1632960000,0.5,19.892326,0.006939625,PRE,us_market,HIKMA PHARMACEUTICALS,0,False,False,2,0.0,72.05 - 72.05,3.622,18.528,72.646,-0.5960007,-0.008204177,67.15674,4.893265,0.07286335,8257434624,3.888709,15,America/New_York,EDT,-14400000,-0.09,,,75.81,59.04,72.65,67.16,514,300,115.39M,,82.22M,0.00%,0.00%,,,,,,1,1.47%,0.50,0.69%,,25.40%,"Sep 29, 2021","Mar 17, 2021",,,"Dec 30, 2020","Dec 30, 2020",18.41%,24.43%,8.86%,20.11%,2.34B,19.84,4.20%,1.21B,686M,431M,3.62,-27.20%,347M,3.01,932M,43.39,1.87,18.53,464M,45.88M,Value,W1S 2HR,Healthcare,8600,5,1,"Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",London,44 20 7399 2760,1,1609372800,1619740800,6,United Kingdom,http://www.hikma.com,86400,4,1 New Burlington Place,44 20 7399 2761,Drug Manufacturers—Specialty & Generic
t-1,HKMPY,1259000000,115386000,37500000,,142000000,13000000,109500000,138500000,318000000,145000000,145000000,-3000000,-8500000,,,,33000000,604500000,459500000,286500000,-3000000,,109000000,109500000,587000000,282000000,1987000000,2135000000,304000000,4135000000,41000000,27000000,1892000000,195000000,289000000,-80000000,235000000,323000000,1028000000,221000000,41000000,-80000000,1068000000,1922000000,34000000,733000000,692000000,757000000,279000000,-1000000,10500000,-91500000,-10500000,-39000000,-12500000,-45000000,-2000000,-500000,86000000,33500000,-29000000,-18000000,-34500000,-50000000,-8500000,27000000,-53000000,894000000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,72.05,1630427382,0.0,72.5,72.05,72.05,360,72.05,0.0,0.0,0,0,finmb_23049465,Other OTC,Hikma Pharmaceuticals PLC,USD,514,300,13.010002,0.22035912,59.04 - 75.81,-3.7599945,-0.049597606,59.04,75.81,1632960000,0.5,19.892326,0.006939625,PRE,us_market,HIKMA PHARMACEUTICALS,0,False,False,2,0.0,72.05 - 72.05,3.622,18.528,72.646,-0.5960007,-0.008204177,67.15674,4.893265,0.07286335,8257434624,3.888709,15,America/New_York,EDT,-14400000,-0.09,,,75.81,59.04,72.65,67.16,514,300,115.39M,,82.22M,0.00%,0.00%,,,,,,1,1.47%,0.50,0.69%,,25.40%,"Sep 29, 2021","Mar 17, 2021",,,"Dec 30, 2020","Dec 30, 2020",18.41%,24.43%,8.86%,20.11%,2.34B,19.84,4.20%,1.21B,686M,431M,3.62,-27.20%,347M,3.01,932M,43.39,1.87,18.53,464M,45.88M,Value,W1S 2HR,Healthcare,8600,5,1,"Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",London,44 20 7399 2760,1,1609372800,1619740800,6,United Kingdom,http://www.hikma.com,86400,4,1 New Burlington Place,44 20 7399 2761,Drug Manufacturers—Specialty & Generic
t-2,HKMPY,1040000000,115386000,31000000,,137000000,10000000,106000000,114500000,288500000,141000000,141000000,2000000,-12000000,,,,31000000,566000000,425000000,277500000,-4000000,,106000000,106000000,570000000,282000000,2070000000,1890000000,427000000,3970000000,41000000,23000000,1723000000,211000000,280000000,-156000000,240000000,413000000,1070000000,234000000,21000000,-156000000,970000000,1878000000,32000000,669000000,730000000,684000000,272000000,-500000,-7500000,-50000000,120500000,-110000000,19000000,-14500000,-185500000,-500000,146000000,29500000,1000000,-36500000,-55500000,26500000,-8500000,25500000,-33000000,808000000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,72.05,1630427382,0.0,72.5,72.05,72.05,360,72.05,0.0,0.0,0,0,finmb_23049465,Other OTC,Hikma Pharmaceuticals PLC,USD,514,300,13.010002,0.22035912,59.04 - 75.81,-3.7599945,-0.049597606,59.04,75.81,1632960000,0.5,19.892326,0.006939625,PRE,us_market,HIKMA PHARMACEUTICALS,0,False,False,2,0.0,72.05 - 72.05,3.622,18.528,72.646,-0.5960007,-0.008204177,67.15674,4.893265,0.07286335,8257434624,3.888709,15,America/New_York,EDT,-14400000,-0.09,,,75.81,59.04,72.65,67.16,514,300,115.39M,,82.22M,0.00%,0.00%,,,,,,1,1.47%,0.50,0.69%,,25.40%,"Sep 29, 2021","Mar 17, 2021",,,"Dec 30, 2020","Dec 30, 2020",18.41%,24.43%,8.86%,20.11%,2.34B,19.84,4.20%,1.21B,686M,431M,3.62,-27.20%,347M,3.01,932M,43.39,1.87,18.53,464M,45.88M,Value,W1S 2HR,Healthcare,8600,5,1,"Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",London,44 20 7399 2760,1,1609372800,1619740800,6,United Kingdom,http://www.hikma.com,86400,4,1 New Burlington Place,44 20 7399 2761,Drug Manufacturers—Specialty & Generic
t-3,HKMPY,1040000000,115386000,31000000,,137000000,10000000,106000000,114500000,288500000,141000000,141000000,2000000,-12000000,,,,31000000,566000000,425000000,277500000,-4000000,,106000000,106000000,570000000,282000000,2070000000,1890000000,427000000,3970000000,41000000,23000000,1723000000,211000000,280000000,-156000000,240000000,413000000,1070000000,234000000,21000000,-156000000,970000000,1878000000,32000000,669000000,730000000,684000000,272000000,-500000,-7500000,-50000000,120500000,-110000000,19000000,-14500000,-185500000,-500000,146000000,29500000,1000000,-36500000,-55500000,26500000,-8500000,25500000,-33000000,808000000,en-US,US,EQUITY,False,Delayed Quote,PNK,USD,72.05,1630427382,0.0,72.5,72.05,72.05,360,72.05,0.0,0.0,0,0,finmb_23049465,Other OTC,Hikma Pharmaceuticals PLC,USD,514,300,13.010002,0.22035912,59.04 - 75.81,-3.7599945,-0.049597606,59.04,75.81,1632960000,0.5,19.892326,0.006939625,PRE,us_market,HIKMA PHARMACEUTICALS,0,False,False,2,0.0,72.05 - 72.05,3.622,18.528,72.646,-0.5960007,-0.008204177,67.15674,4.893265,0.07286335,8257434624,3.888709,15,America/New_York,EDT,-14400000,-0.09,,,75.81,59.04,72.65,67.16,514,300,115.39M,,82.22M,0.00%,0.00%,,,,,,1,1.47%,0.50,0.69%,,25.40%,"Sep 29, 2021","Mar 17, 2021",,,"Dec 30, 2020","Dec 30, 2020",18.41%,24.43%,8.86%,20.11%,2.34B,19.84,4.20%,1.21B,686M,431M,3.62,-27.20%,347M,3.01,932M,43.39,1.87,18.53,464M,45.88M,Value,W1S 2HR,Healthcare,8600,5,1,"Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",London,44 20 7399 2760,1,1609372800,1619740800,6,United Kingdom,http://www.hikma.com,86400,4,1 New Burlington Place,44 20 7399 2761,Drug Manufacturers—Specialty & Generic
